Selected as a Key Oral Presentation at CTAD

52-week Efficacy and Safety Results to Be Unveiled

Topline Results to Be Released Separately Upon Completion

Aribio announced on July 22 that the results of the global Phase 3 clinical trial (POLARIS-AD) for AR1001, its oral Alzheimer's disease treatment candidate, will be presented at the 19th Clinical Trials on Alzheimer's Disease conference (CTAD 2026) to be held in Boston, USA in November.


Aribio company logo image. Aribio

Aribio company logo image. Aribio

View original image

The Phase 3 trial results for AR1001 will be unveiled during the first oral presentation session on November 16, the opening day of the conference. The presentation will be delivered by Sharon Sha, Professor at Stanford University School of Medicine, who served as the global principal investigator for the Phase 3 trial.


The presentation will cover the topic "Global Phase 3 trial POLARIS-AD of AR1001 in Patients with Early Alzheimer's Disease: 52-Week Efficacy Results and Extension Study Safety."

POLARIS-AD is a global Phase 3 trial conducted at approximately 230 institutions in 13 countries, including the United States, Canada, Europe, Korea, and China, targeting 1,535 patients with early Alzheimer's disease. The 52-week dosing for the last patient was completed in June 2026, and the study is currently undergoing data cleaning, database lock, and statistical analysis.


At the conference, Aribio plans to announce the efficacy and safety outcomes of the 52-week double-blind study, analyses of the monotherapy group, primary endpoints and subgroups, as well as safety data collected from the extension study. The topline results will be released immediately after the analyses are completed, independent of the conference schedule. CTAD is an international academic conference focused on clinical development and regulatory strategies for Alzheimer's disease treatments and is a venue where significant clinical trial results are shared.



Aribio CEO Jeong Jaejoon stated, "After presenting at CTAD, we plan to pursue new drug application procedures through consultations with global regulatory agencies, based on the primary clinical results."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing